颅咽管瘤患者下丘脑性肥胖的减重手术:回顾性配对病例对照研究
该回顾性、病例对照、多中心国际研究纳入16例有减重手术史的肥胖颅咽管瘤患者(12例女性,12例RYGB,4例袖状胃切除)及155例年龄/性别/术式/BMI匹配的肥胖对照,比较术后5年体重下降及肥胖相关合并症。患者5年平均减重22.0%(95%CI 16.1%-27.8%),低于对照的29.5%(95%CI 28.0%-30.9%,P=.02);RYGB后减重较少,袖状胃切除后与对照相似。术后内分泌替代治疗无重大变化,减重手术对肥胖颅咽管瘤患者有效且相对安全。
要点
- 肥胖颅咽管瘤患者减重术后5年平均减重22%,低于匹配对照的29.5%。
- RYGB后患者减重少于对照,袖状胃切除后与对照相似。
- 术后内分泌替代治疗无重大变化,减重手术相对安全。
核心结论
- 肥胖颅咽管瘤患者减重术后5年平均减重22%,独立于减重手术术式。
- RYGB后患者减重低于肥胖对照,袖状胃切除后与对照相似。
- 减重手术对肥胖颅咽管瘤患者有效且相对安全。
研究设计与样本
- 回顾性、病例对照、多中心国际研究。
- 纳入16例肥胖颅咽管瘤患者(12例女性;12例RYGB,4例袖状胃切除;中位年龄21岁,范围15-52岁;中位随访5.2年,范围2.0-11.3年)。
- 纳入155例年龄/性别/术式/BMI匹配的肥胖对照。
主要发现
- 5年随访平均减重:患者22.0%(95%CI 16.1%-27.8%),对照29.5%(95%CI 28.0%-30.9%),P=.02。
- RYGB后平均减重:患者22.7%(95%CI 16.9%-28.5%),对照32.0%(95%CI 30.4%-33.6%),P=.003。
- 袖状胃切除后平均减重:患者21.7%(95%CI -1.8%至45.2%),对照21.8%(95%CI 18.2%-25.5%),P=.96。
- 术后内分泌替代治疗无重大变化。
- 1例患者死亡(原因不明),1例患者有长期吸收问题。
临床怎么用
- 减重手术可作为肥胖颅咽管瘤患者下丘脑性肥胖的治疗选择,需告知RYGB后减重可能低于普通肥胖人群。
- 术后应继续监测内分泌替代治疗,无需预期重大调整。
局限性
- 回顾性设计,样本量小(患者16例)。
- 1例死亡原因不明,1例长期吸收问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Craniopharyngioma is a sellar tumor associated with high rates of pituitary deficiencies (~ 98%) and hypothalamic obesity (~ 50%). OBJECTIVE: This work aims to determine the efficacy regarding long-term weight loss after bariatric surgery in obese craniopharyngioma patients with hypothalamic dysfunction. METHODS: This retrospective, case-control, multicenter, international study included obese craniopharyngioma patients (N = 16; of whom 12 are women) with a history of bariatric surgery (12 Roux-en-Y gastric bypass, 4 sleeve gastrectomy; median age 21 years [range, 15-52 years], median follow-up 5.2 years [range, 2.0-11.3 years]) and age/sex/surgery/body mass index-matched obese controls (N = 155). Weight loss and obesity-related comorbidities up to 5 years after bariatric surgery were compared and changes in hormonal replacement therapy evaluated. RESULTS: Mean weight loss at 5-year follow-up was 22.0% (95% CI, 16.1%-27.8%) in patients vs 29.5% (95% CI, 28.0%-30.9%) in controls (P = .02), which was less after Roux-en-Y gastric bypass (22.7% [16.9%-28.5%] vs 32.0% [30.4%-33.6%]; P = .003) but at a similar level after sleeve gastrectomy (21.7% [-1.8% to 45.2%] vs 21.8% [18.2%-25.5%]; P = .96). No major changes in endocrine replacement therapy were observed after surgery. One patient died (unknown cause). One patient had long-term absorptive problems. CONCLUSION: Obese patients with craniopharyngioma had a substantial mean weight loss of 22% at 5-year follow-up after bariatric surgery, independent of type of bariatric surgery procedure. Weight loss was lower than in obese controls after Roux-en-Y gastric bypass. Bariatric surgery appears to be effective and relatively safe in the treatment of obese craniopharyngioma patients.
引用
- van Santen SS, Wolf P, Kremenevski N, et al. Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. J Clin Endocrinol Metab. 2021. PMID: 34265053. doi:10.1210/clinem/dgab518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。